MODERN ASPECTS OF THE TREATMENT OF HEMOPHILIA. II.
Ways of obtaining "two-donor" fibrinogen, as described in an earlier communication,(1) with an optimal and more constant amount of Factor VIII activity were investigated. Four modifications of the method as originally described by Nitschmann et al. are described. This freshly prepared modified "two-donor" fibrinogen was used in the treatment of severe or moderately severe hemorrhage in 20 hemophiliacs. Comparison of the results with those obtained by intermittent transfusions of fresh plasma or fresh blood indicated that the modified "two-donor" fibrinogen was definitely the preferable preparation.
D001803:Blood Transfusion; D003029:Coagulants; D003142:Communication; D005110:Extracellular Space; D005169:Factor VIII; D005340:Fibrinogen; D006467:Hemophilia A; D006470:Hemorrhage; D006490:Hemostatics; D006801:Humans; D010949:Plasma; D017713:Platelet Transfusion; D014019:Tissue Donors
D003029:Coagulants; D006490:Hemostatics; C427184:recombinant factor VIII SQ; D005169:Factor VIII; D005340:Fibrinogen
BLOOD TRANSFUSION; FACTOR VIII; FIBRINOGEN; HEMOPHILIA